Reduction of susceptibility to upper respiratory tract infections in Down syndrome children following treatment with GABAergic drugs: report of 70 cases.
D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D004198:Disease Susceptibility / Q000517:prevention & control; D004314:Down Syndrome / Q000150:complications*; D005260:Female; D005973:Glutamine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011736:Pyridoxine / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000209:etiology / Q000517:prevention & control*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D005973:Glutamine; D001569:Benzodiazepines; D005680:gamma-Aminobutyric Acid; D011736:Pyridoxine